| Embassy Of Cambridge | |
| 1471 Wills Creek Valley Drive, Cambridge, Ohio 43725 | |
| (740) 439-4437 | |
| Name | Embassy Of Cambridge |
|---|---|
| Location | 1471 Wills Creek Valley Drive, Cambridge, Ohio |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 95 |
| Occupancy Rate | 72.42% |
| Medicare ID (CCN) | 365770 |
| Legal Business Name | Embassy Cambridge, Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1114344868 |
| Organization Name | CAMBRIDGE HEALTH CARE LLC |
| Doing Business As | CAMBRIDGE HEALTH & REHABILITATION CENTER |
| Address | 1471 Wills Creek Valley Dr, Cambridge, OH 43725 |
| Phone Number | 740-439-4437 |
News Archive
Today's Medicare demonstration project might determine how physicians interact with the program tomorrow, so naturally such projects generate a lot of buzz in the health care community. Lately, some of that buzz has been about how demos might provide part of the solution for Medicare's payment problems.
NovaBay Pharmaceuticals, Inc. announced today that its development partner, Alcon Research, Ltd., has concluded its proof of concept clinical trial of NovaBay's patented lead Aganocide compound, NVC-422 for the treatment of viral conjunctivitis a highly contagious eye infection for which there are currently no marketed products.
Astellas today announced topline results from the Phase 3 ACTIVE study evaluating the efficacy and safety of intravenous (IV) and oral isavuconazole, commercially known as CRESEMBA (isavuconazonium sulfate), under development for adults with candidemia and other invasive Candida infections.
BIOCRATES Life Sciences AG, a global leader in targeted metabolomics, reported today the Alzheimer's Disease Metabolomics Consortium's new breakthrough in Alzheimer's research, which connects the Gut-Liver-Brain axis in the development and progression of Alzheimer's disease (AD). During the Alzheimer's Association International Conference, Chicago, USA, researchers reported new data on how gut bacteria and lipid metabolism may influence AD.
› Verified 6 days ago
| NPI Number | 1265066054 |
| Organization Name | EMBASSY CAMBRIDGE, LLC |
| Address | 1471 Wills Creek Valley Dr, Cambridge, OH 43725 |
| Phone Number | 740-439-4437 |
News Archive
Today's Medicare demonstration project might determine how physicians interact with the program tomorrow, so naturally such projects generate a lot of buzz in the health care community. Lately, some of that buzz has been about how demos might provide part of the solution for Medicare's payment problems.
NovaBay Pharmaceuticals, Inc. announced today that its development partner, Alcon Research, Ltd., has concluded its proof of concept clinical trial of NovaBay's patented lead Aganocide compound, NVC-422 for the treatment of viral conjunctivitis a highly contagious eye infection for which there are currently no marketed products.
Astellas today announced topline results from the Phase 3 ACTIVE study evaluating the efficacy and safety of intravenous (IV) and oral isavuconazole, commercially known as CRESEMBA (isavuconazonium sulfate), under development for adults with candidemia and other invasive Candida infections.
BIOCRATES Life Sciences AG, a global leader in targeted metabolomics, reported today the Alzheimer's Disease Metabolomics Consortium's new breakthrough in Alzheimer's research, which connects the Gut-Liver-Brain axis in the development and progression of Alzheimer's disease (AD). During the Alzheimer's Association International Conference, Chicago, USA, researchers reported new data on how gut bacteria and lipid metabolism may influence AD.
› Verified 6 days ago
| NPI Number | 1346403615 |
| Organization Name | KINDRED NURSING CENTERS EAST LLC |
| Doing Business As | CAMBRIDGE HEALTH & REHABILITATION CENTER |
| Address | 1471 Wills Creek Valley Dr, Cambridge, OH 43725 |
| Phone Number | 740-439-4437 |
News Archive
Today's Medicare demonstration project might determine how physicians interact with the program tomorrow, so naturally such projects generate a lot of buzz in the health care community. Lately, some of that buzz has been about how demos might provide part of the solution for Medicare's payment problems.
NovaBay Pharmaceuticals, Inc. announced today that its development partner, Alcon Research, Ltd., has concluded its proof of concept clinical trial of NovaBay's patented lead Aganocide compound, NVC-422 for the treatment of viral conjunctivitis a highly contagious eye infection for which there are currently no marketed products.
Astellas today announced topline results from the Phase 3 ACTIVE study evaluating the efficacy and safety of intravenous (IV) and oral isavuconazole, commercially known as CRESEMBA (isavuconazonium sulfate), under development for adults with candidemia and other invasive Candida infections.
BIOCRATES Life Sciences AG, a global leader in targeted metabolomics, reported today the Alzheimer's Disease Metabolomics Consortium's new breakthrough in Alzheimer's research, which connects the Gut-Liver-Brain axis in the development and progression of Alzheimer's disease (AD). During the Alzheimer's Association International Conference, Chicago, USA, researchers reported new data on how gut bacteria and lipid metabolism may influence AD.
› Verified 6 days ago
| NPI Number | 1578003570 |
| Organization Name | CAMBRIDGE HEALTH LEASING, LLC |
| Address | 1471 Wills Creek Valley Dr, Cambridge, OH 43725 |
| Phone Number | 740-439-4437 |
News Archive
Today's Medicare demonstration project might determine how physicians interact with the program tomorrow, so naturally such projects generate a lot of buzz in the health care community. Lately, some of that buzz has been about how demos might provide part of the solution for Medicare's payment problems.
NovaBay Pharmaceuticals, Inc. announced today that its development partner, Alcon Research, Ltd., has concluded its proof of concept clinical trial of NovaBay's patented lead Aganocide compound, NVC-422 for the treatment of viral conjunctivitis a highly contagious eye infection for which there are currently no marketed products.
Astellas today announced topline results from the Phase 3 ACTIVE study evaluating the efficacy and safety of intravenous (IV) and oral isavuconazole, commercially known as CRESEMBA (isavuconazonium sulfate), under development for adults with candidemia and other invasive Candida infections.
BIOCRATES Life Sciences AG, a global leader in targeted metabolomics, reported today the Alzheimer's Disease Metabolomics Consortium's new breakthrough in Alzheimer's research, which connects the Gut-Liver-Brain axis in the development and progression of Alzheimer's disease (AD). During the Alzheimer's Association International Conference, Chicago, USA, researchers reported new data on how gut bacteria and lipid metabolism may influence AD.
› Verified 6 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Today's Medicare demonstration project might determine how physicians interact with the program tomorrow, so naturally such projects generate a lot of buzz in the health care community. Lately, some of that buzz has been about how demos might provide part of the solution for Medicare's payment problems.
NovaBay Pharmaceuticals, Inc. announced today that its development partner, Alcon Research, Ltd., has concluded its proof of concept clinical trial of NovaBay's patented lead Aganocide compound, NVC-422 for the treatment of viral conjunctivitis a highly contagious eye infection for which there are currently no marketed products.
Astellas today announced topline results from the Phase 3 ACTIVE study evaluating the efficacy and safety of intravenous (IV) and oral isavuconazole, commercially known as CRESEMBA (isavuconazonium sulfate), under development for adults with candidemia and other invasive Candida infections.
BIOCRATES Life Sciences AG, a global leader in targeted metabolomics, reported today the Alzheimer's Disease Metabolomics Consortium's new breakthrough in Alzheimer's research, which connects the Gut-Liver-Brain axis in the development and progression of Alzheimer's disease (AD). During the Alzheimer's Association International Conference, Chicago, USA, researchers reported new data on how gut bacteria and lipid metabolism may influence AD.
› Verified 6 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 2 |
| Total Number of Penalties | 2 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 10 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 9 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 27.07 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0.83 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 1.27 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 3.64 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 12.71 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 88.84 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 2.63 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 18.98 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 25.81 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 8.2 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 97.95 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 81.32 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 82.67 | 82.93 |
News Archive
Today's Medicare demonstration project might determine how physicians interact with the program tomorrow, so naturally such projects generate a lot of buzz in the health care community. Lately, some of that buzz has been about how demos might provide part of the solution for Medicare's payment problems.
NovaBay Pharmaceuticals, Inc. announced today that its development partner, Alcon Research, Ltd., has concluded its proof of concept clinical trial of NovaBay's patented lead Aganocide compound, NVC-422 for the treatment of viral conjunctivitis a highly contagious eye infection for which there are currently no marketed products.
Astellas today announced topline results from the Phase 3 ACTIVE study evaluating the efficacy and safety of intravenous (IV) and oral isavuconazole, commercially known as CRESEMBA (isavuconazonium sulfate), under development for adults with candidemia and other invasive Candida infections.
BIOCRATES Life Sciences AG, a global leader in targeted metabolomics, reported today the Alzheimer's Disease Metabolomics Consortium's new breakthrough in Alzheimer's research, which connects the Gut-Liver-Brain axis in the development and progression of Alzheimer's disease (AD). During the Alzheimer's Association International Conference, Chicago, USA, researchers reported new data on how gut bacteria and lipid metabolism may influence AD.
› Verified 6 days ago
Embassy Of Cambridge Location: 1471 Wills Creek Valley Drive, Cambridge, Ohio 43725 Phone: (740) 439-4437 | |
Altercare Cambridge Inc. Location: 66731 Old Twenty-one Road, Cambridge, Ohio 43725 Phone: (740) 432-7717 | |
Astoria Place Of Cambridge Location: 8420 Georgetown Road, Cambridge, Ohio 43725 Phone: (740) 439-4401 |